The Oncotype DX® Breast Cancer Assay is a 21-gene assay that provides a Recurrence Score® (RS), which is divided into low-, intermediate- and high-risk categories in relation to the likelihood of breast cancer recurrence. At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA, discusses adjuvant treatment decisions in early breast cancer patients with intermediate Oncotype DX RS results.
This content is supported by Genomic Health, Inc.
European Medical Journal
Advertisement
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews